Literature DB >> 11137617

Immunostimulation by bacterial components: II. Efficacy studies and meta-analysis of the bacterial extract OM-89.

M Huber1, K Krauter, G Winkelmann, H W Bauer, V W Rahlfs, P A Lauener, G S Blessmann, W G Bessler.   

Abstract

The bacterial extract OM-89 (Uro-Vaxom) consisting of immunostimulating components derived from 18 Escherichia coli strains is used for the treatment of recurrent urinary tract infections. We investigated in the mouse the immunogenicity of the bacterial extract after oral administration. After repeated administration of OM-89, a specific serum IgG and IgA response against a number of bacterial strains was obtained. Supernatants of cell cultures prepared from the urogenital tract of immunized mice also contained increased levels of strain specific IgG and IgA. We could show a bias towards a Th1 type immune response as indicated by increased IgG2a levels in sera, and increased IFNgamma levels in supernatants of spleen cells. These findings may contribute to an understanding of the therapeutic effect of Uro-Vaxom: the metaanalysis of several clinical studies confirmed that Uro-Vaxom constitutes an effective prophylaxis for urinary tract infections.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11137617     DOI: 10.1016/s0192-0561(00)00070-9

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  5 in total

1.  Vaccine Development for the Prevention of Urinary Tract Infections.

Authors:  Walter J. Hopkins; David T. Uehling
Journal:  Curr Infect Dis Rep       Date:  2002-12       Impact factor: 3.725

2.  A Retrospective Study of Immunotherapy Treatment with Uro-Vaxom (OM-89®) for Prophylaxis of Recurrent Urinary Tract Infections.

Authors:  Andrew Brodie; Omar El-Taji; Ibrahim Jour; Charlotte Foley; Damian Hanbury
Journal:  Curr Urol       Date:  2020-10-13

3.  Intranasal immunization with a colloid-formulated bacterial extract induces an acute inflammatory response in the lungs and elicits specific immune responses.

Authors:  A Rial; D Lens; L Betancor; H Benkiel; J S Silva; J A Chabalgoity
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

Review 4.  Drug and Vaccine Development for the Treatment and Prevention of Urinary Tract Infections.

Authors:  Valerie P O'Brien; Thomas J Hannan; Hailyn V Nielsen; Scott J Hultgren
Journal:  Microbiol Spectr       Date:  2016-02

5.  Enhanced Mucosal Antibody Production and Protection against Respiratory Infections Following an Orally Administered Bacterial Extract.

Authors:  Christian Pasquali; Olawale Salami; Manisha Taneja; Eva S Gollwitzer; Aurelien Trompette; Céline Pattaroni; Koshika Yadava; Jacques Bauer; Benjamin J Marsland
Journal:  Front Med (Lausanne)       Date:  2014-10-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.